arGentis Expands Scientific Advisory Board

arGentis Pharmaceuticals, LLC announced today that the company has added new members to its Scientific Advisory Board overseeing development of autoimmune related therapies.

Dr. Arnold Postlethwaite, Chief Medical Officer and Chairman of arGentis Pharmaceutical's Scientific Advisory Board stated, "Our post Phase II data analysis, along with the discovery of a genetic marker highly associated with the induction of oral immune tolerance in systemic sclerosis patients, have opened the door for additional study and development of ARG201 as an effective immunoregulatory therapy. I am extremely pleased that my colleagues, Drs. Mayes, Furst, Steen and Wong will be joining me in advising arGentis Pharmaceuticals on these exciting developments and their paths to commercialization."

 

Comments

Post a Comment

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Image
GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut    Vox Author of GOP Tax Plan Says Children's Health Insurance Program Is Held Up “Because We Don't Have Money ...    The Intercept Nevada wins short reprieve in child health care funds fight    Sacramento Bee Ben McAdams: Congress to Tiny Tim: 'No health insurance for you.'    Salt Lake Tribune Full coverage
Read more

Trump wants more mental health care; Alabama says it's trying

Image
Trump wants more mental health care; Alabama says it's trying    AL.com Budget undercuts Trump focus on mental health, school safety    Yahoo News Mental health awareness license plates offered by New York State DMV    Buffalo News Trump wants to 'tackle the difficult issue of mental health?' He should put his money where his mouth is.    Washington Post Full coverage
Read more